Physician profile
Olabode Agaja
NPI 1285167759
$1,772.05
in general payments reported to CMS, 2019-2025
14 companies · $387 in 2025
The $387 reported for 2025 was more than what 93% of Sports Medicine (Pediatrics) providers received nationally (typical 2025 total: $59.86).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.18 · 2021: $125 · 2022: $478 · 2023: $269 · 2024: $494 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $508.61 | 2022-2025 | Maci |
| Smith+Nephew, INC. | $253.99 | 2022-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Linvatec Corporation | $144.52 | 2023 | Biobrace 23mm |
| Bioventus LLC | $141.46 | 2024 | Durolane |
| Ossur Americas, INC. | $133.15 | 2025 | Unloader One X |
| Pacira Therapeutics, INC. | $125.01 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $124.69 | 2022 | |
| Stryker Corporation | $112.04 | 2022 | |
| Hydrocision, INC. | $81.57 | 2025 | Tenjet |
| Alon Medical Technology | $76.00 | 2024 | |
| Abbvie INC. | $19.83 | 2025 | |
| Pfizer INC. | $19.18 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.75 | 2025 | Euflexxa |
| Lilly USA, LLC | $14.25 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olabode Agaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.